Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curanex PharmaceuticalsCURX -4.88%12 Current Ratio is 45.95 as of Jun. 2026, which is 16% below its 10-year median of 54.42. GuruFocus rates CURX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,407 Biotechnology companies, Curanex Pharmaceuticals ranks better than 98.37% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Curanex Pharmaceuticals's current ratio for the quarter that ended in Jun. 2026 was 45.95.
Curanex Pharmaceuticals has a current ratio of 45.95. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Curanex Pharmaceuticals's Current Ratio or its related term are showing as below:
CURX'
s Current Ratio Range Over the Past 10 Years
Min: 3.61 Med: 54.42 Max: 666
Current: 46.09
During the past 3 years, Curanex Pharmaceuticals's highest Current Ratio was 666.00. The lowest was 3.61. And the median was 54.42.
CURX's Current Ratio is ranked better than 98.37% of 1407
companies
in the Biotechnology industry
Industry Median: 3.94
vs CURX: 46.09
Curanex Pharmaceuticals (NAS:CURX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Curanex Pharmaceuticals Current Ratio Related Terms
Curanex Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CURX vs NCNA, BOLT, ADTX: Current Ratio Comparison
For the Biotechnology subindustry, Curanex Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curanex Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Curanex Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Curanex Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curanex Pharmaceuticals (CURX) has a Current Ratio of 45.95 as of Jun. 2026. This is 16% below median its historical median of 54.42. Over the past decade, Curanex Pharmaceuticals' Current Ratio has ranged from 3.61 to 666.00. According to the industry distribution chart, Curanex Pharmaceuticals ranks #23 out of 1407 companies in the Biotechnology industry, placing it in the top 1.6%.
Is Curanex Pharmaceuticals' Current Ratio too high?
Curanex Pharmaceuticals' current Current Ratio of 45.95 is 16% below median its 10-year median of 54.42. Over the past 10 years, this metric has ranged from a low of 3.61 to a high of 666.00. The Biotechnology industry median Current Ratio is 3.94. Curanex Pharmaceuticals' value of 45.95 is 1066.2% above this industry median. Based on the distribution chart, Curanex Pharmaceuticals ranks #23 out of 1407 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Curanex Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Curanex Pharmaceuticals' Current Ratio compare to NCNA and BOLT?
According to the Biotechnology industry distribution chart, Curanex Pharmaceuticals ranks #23 out of 1407 companies for Current Ratio. This places Curanex Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.94. Curanex Pharmaceuticals' value of 45.95 is 1066.2% above this benchmark. Historically, Curanex Pharmaceuticals' own Current Ratio has ranged from 3.61 to 666.00 over the past decade. While the company's 10-year median is 54.42 vs. the industry median of 3.94, Curanex Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.94, based on 1,407 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curanex Pharmaceuticals's current Current Ratio of 45.95 is 1066.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curanex Pharmaceuticals's current Current Ratio is 45.95, which is 16% below median its own 10-year median of 54.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curanex Pharmaceuticals stock overvalued right now?
Curanex Pharmaceuticals (CURX) has a current Current Ratio of 45.95. The current Current Ratio is 45.95, which is 16% below median its 10-year median of 54.42 and 1066.2% above the Biotechnology industry median of 3.94. Curanex Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Curanex Pharmaceuticals (CURX), the current Current Ratio is 45.95 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.
12GF Score
Get the complete analysis for CURX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURX has been successfully added to your 
